(Recasts with confirmation)
Oct 23 (Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by U.S. regulators, the company said on Friday.
AstraZeneca’s U.S. trial was paused on Sept. 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company’s UK trial. (Reporting by Munsif Vengattil and Carl O’Donnell; Editing by Anil D’Silva and Rosalba O’Brien)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.